EUR 103.14
(-0.33%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 42.17 Billion DKK | 30.38% |
2022 | 32.34 Billion DKK | 23.68% |
2021 | 26.15 Billion DKK | 34.33% |
2020 | 19.46 Billion DKK | 15.82% |
2019 | 16.8 Billion EUR | 13.25% |
2018 | 14.84 Billion EUR | 7.97% |
2017 | 13.74 Billion EUR | 4.8% |
2016 | 13.11 Billion EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 369.38 Billion DKK | 23.57% |
2024 Q1 | 39.97 Billion DKK | -4.95% |
2023 FY | 42.17 Billion DKK | 30.38% |
2023 Q2 | 37.6 Billion DKK | 12.27% |
2023 Q4 | 42.17 Billion DKK | 5.07% |
2023 Q1 | 33.49 Billion DKK | 3.55% |
2023 Q3 | 40.14 Billion DKK | 6.75% |
2022 Q4 | 32.34 Billion DKK | -0.65% |
2022 Q2 | 29.35 Billion EUR | 10.75% |
2022 Q3 | 32.55 Billion EUR | 10.93% |
2022 Q1 | 26.5 Billion EUR | 1.33% |
2021 Q4 | 26.15 Billion EUR | 11.73% |
2021 Q3 | 23.4 Billion EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
BioNTech SE | 23 Billion EUR | -83.323% |
CureVac N.V. | 788.89 Million EUR | -5246.165% |
Biotest Aktiengesellschaft | 1.44 Billion EUR | -2820.158% |
Biotest Aktiengesellschaft | 1.44 Billion EUR | -2820.158% |
BRAIN Biotech AG | 70.93 Million EUR | -59355.347% |
Formycon AG | 890.36 Million EUR | -4636.932% |
Heidelberg Pharma AG | 70.35 Million EUR | -59848.858% |
Medigene AG | 31.71 Million EUR | -132879.693% |